| Literature DB >> 26202978 |
Deborah M Stephens1, Amy S Ruppert2, William G Weirda3, Jeffrey A Jones2,4, Jennifer A Woyach2,4, Kami Maddocks2,4, Samantha M Jaglowski2,4, Leslie A Andritsos2,4, Joseph M Flynn2,4, Michael R Grever2,4, Gerard Lozanski5, Constantine Tam6, Susan O'Brien3, Michael J Keating3, Natarajan Muthusamy2,4, Lynne V Abruzzo2,4, Nyla A Heerema2,7, John C Byrd2,4,8.
Abstract
Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially preventing unnecessary use of aggressive therapies.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26202978 PMCID： PMC7055503 DOI： 10.1002/ajh.24125
Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047